

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

4821-406-999

APPLICATION NO.

09/722,477

APPLICANT

J. McCullough et al.

FILING DATE

November 28, 2000

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,763,493	6/9/98	Ruff et al.	514	617	
	AB	5,753,712	5/19/98	Pinsker	514	649	
	AC	5,731,000	3/24/98	Ruff et al.	424	451	
	AD	5,541,231	7/30/96	Ruff et al.	514	649	
	AE	5,512,593	4/30/96	Dante	514	410	
	AF	5,447,948	9/5/95	Seibyl et al.	514	393	
	AG	5,427,798	6/27/95	Ludwig et al.	424	464	
	AH	5,358,970	10/25/94	Ruff et al.	514	649	
	AI	5,217,987	6/8/93	Berger	514	416	
	AJ	4,935,439	6/19/90	Kashman et al.	514	475	
	AK	4,935,429	6/19/90	Dackis et al.	514	288	
	AL	4,895,845	1/23/90	Seed	514	252	
	AM	4,868,344	9/19/89	Brown	568	812	
	AN	4,835,147	5/30/89	Roberts	514	178	
	AO	4,798,826	1/17/89	Peck	514	221	
	AP	4,769,027	9/6/88	Baker et al.	424	493	
	AQ	4,687,660	8/18/87	Baker et al.	424	465	
	AR	4,656,026	4/7/87	Coffman et al.	424	9	
	AS	4,571,395	2/18/86	Peck	514	221	
	AT	4,507,323	3/26/85	Stern	514	649	
	AU	4,438,138	3/20/84	Stern	424	330	
	AV	4,435,449	3/6/84	Stern	424	330	
	AW	4,425,363	1/10/84	Stern	424	330	
	AX	4,393,078	7/12/83	Peck	424	330	
	AY	4,356,165	10/26/82	Findlay et al.	424	1	
	AZ	4,355,179	10/19/82	Findlay et al.	564	177	
	BA	4,347,382	8/31/82	Scharver	564	183	
	BB	4,347,257	8/31/82	Stern	424	330	
	BC	4,347,178	8/31/82	Findlay et al.	260	112 B	
	BD	4,347,177	8/31/82	Phillips	260	112 B	
	BE	4,347,176	8/31/82	Mehta	260	112 B	
	BF	4,008,719	2/22/77	Theeuwes et al.	128	260	
	BG	3,960,927	6/1/76	Metcalf et al.	260	471A	

BH	3,916,899	11/4/75	Theeuwes et al.	128	260	TECH CENTER 1600/2900	JUL 30 2001
BI	3,885,046	5/20/75	Mehta	424	330		
BJ	3,845,770	11/5/74	Theeuwes et al.	128	260		
BK	3,819,706	6/25/74	Mehta	260	570.5C		
BL	3,630,200	12/28/71	Higuchi	128	260		
BM	3,622,675	11/23/71	Koppe et al.				
BN	3,598,123	8/10/71	Zaffaroni	128	268		
BO	3,536,809	10/27/70	Applezweig	424	28		
BP	RE 33,994	7/14/92	Baker et al.	424	465		

FOREIGN PATENT DOCUMENTS


DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
WO 95/22324	8/24/95	PCT WO				
BR WO 94/20100	9/15/94	PCT WO				
BS WO 94/04138	3/3/94	PCT WO				
BT WO 93/21917	11/11/93	PCT WO				
BU WO 91/11184	8/8/91	PCT WO				
BV WO 92/19226	11/12/92	PCT WO				
BW WO 95/03791	2/09/95	PCT WO				
BX WO 96/39133	12/12/96	PCT WO				
BY WO 97/29735	8/21/97	PCT WO				
BZ WO 98/50044	11/12/98	PCT WO				
CA WO 99/37305	7/29/99	PCT WO				
CB 0 467 488	1/22/92	EPO				
CC 0 171 227	2/12/86	EPO				
CD 0 118 036	9/12/84	EPO				
CE 977778	11/11/75	CA				
CF 977777	11/11/75	CA				
CG 63-91352	4/22/88	JP				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CH	Ascher, J.A. et al., 1995, "Bupropion: a review of its mechanism of antidepressant activity", J. Clin. Psych. 56:395-401.
CI	Bannon et al., 1998, "Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors", Science 279:77-81.
CJ	Bischoff et al., 1984, "Affinity changes of rat striatal dopamine receptor in vivo after acute bupropion treatment", Eur. J. Pharmacol. 104:173-176.
CK	Blondel-Hill et al., 1993, "Treatment of the chronic fatigue syndrome", Drugs 46(4):639-651.
CL	Borowski, T.B. et al., 1993, "Amphetamine and antidepressant drug effects on GABA- and NMDA-related seizures", Brain Res. Bull. 30:607-610.
CM	Calabrese, J.R. et al., 1991, "Treatment of depression", Primary Care 18(2):421-433.


JUL 3 0 2001

✓	CN	Castaldi, G. et al., 1987, "Tartaric acid, an efficient chiral auxiliary: new asymmetric synthesis of 2-alkyl-2-arylacetic acids", J. Org. Chem. 52:3018.
	CO	Castello, R.A. and Mattocks, A.M., J. Pharm. Sci. 51(2):106-108 (1962).
	CP	Charney, D.S. et al, 1983, "Monoamine receptor sensitivity and depression: clinical studies of antidepressant effects on serotonin and noradrenergic function," Psychopharmacol. Bull 19(3):490.
	CQ	Clay et al., 1988, "Clinical and neuropsychological effects of the novel antidepressant bupropion", Psychopharma. Bull. 24(1):143-148.
	CR	Conners, K.C. et al., 1996, "Bupropion hydrochloride in attention deficit disorder with hyperactivity", J. Am. Acad. Child Adolesc. Psychiatr. 34(10):1314-1321.
	CS	Cooke C.E., 1997, "Therapeutic advances in the treatment of cigarette addiction", J. Pharmacy Practice 10(5):329-337.
	CT	Cooper, B.R. et al., 1994, "Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin®) are mediated by a noradrenergic mechanism", Neuropsychopharmacology 11(2):133-141.
	CU	Coutts, R.T. & Baker, G.B., 1989, "Implications of chirality and geometric isomerisms in some psychoactive drugs and their metabolites", Chirality 1:99-120.
	CV	Crenshaw et al., 1987, "Pharmacological modification of psychosexual dysfunction", J. Sex. Marital Ther. 13(4):239-252.
	CW	Cusack, B. et al., 1994, "Binding of antidepressants to human brain receptors: focus on newer generation compounds", Psychopharmacol. 114:559-565.
	CX	Davidson et al., 1994, "Bupropion in chronic low back pain", J. Clin. Psychiatry 55(8):362.
	CY	Dilsaver, S.C. et al., 1992, "The efficacy of bupropion in winter depression: results of an open trial", J. Clin. Psychiatry 53(7):252-255.
	CZ	Eliel, E.L., 1962, Stereochemistry of Carbon Compounds, McGraw-Hill, NY.
	DA	Ferris, R.M. et al., 1983, "Studies of bupropion's mechanism of antidepressant activity", J. Clin. Psychiatry 44(5):74-78.
	DB	Ferris & Beaman, 1983, "Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β -adrenergic, serotonergic (5-HT ₂), α_2 -adrenergic, imipramine and dopaminergic receptors in brain", Neuropharmacol. 22(1):1257-1267.
	DC	Ferry, L.H. et al, 1992, "Enhancement of smoking cessation using the anti-depressant bupropion hydrochloride" (abstract) Circulation 86:671.
	DD	Ferry, L.H. et al., 1994, "Efficacy of bupropion for smoking cessation in non-depressed smokers," J. Addict, Dis. 13:A9.
	DE	Fisher, R.S., 1989, "Animal models of the epilepsies", Brain Res. Reviews 14:245-278.
	DF	Foote et al., 1984, "Proconvulsant effect of morphine on seizures induced by pentylentetrazol in the rat", 105:179-184.
	DG	Garland et al., 1998, "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats", J. Psychopharmacology 12(4):385-395.
	DH	Goetz et al., 1984, "Bupropion in Parkinson's Disease," 34:1092-4.
	DI	Goodnick, P.J., 1994, "Pharmacokinetic optimisation of therapy with newer antidepressants", Clin. Pharmacokinet. 27(4):307-330.
✓	DJ	Goodnick, P.J. & Sandoval, R., 1993, "Psychotropic treatment of depression: results of an open trial", J. Clin. Psych. 54(1):13-20.




JUL 30 2001

2	DK	Green, A.R. & Murray, T.K., 1989, "A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms", J. Pharm. Pharmacol. 41:879-880.
	DL	Grimes et al., 1996, "Spontaneous orgasm with the combined use of bupropion and sertraline", Soc. Biol. Psych. 40:1184-1185.
	DM	Handbook of Pharmaceutical Excipients, 2nd ed., Wade and Willer eds., pp. 257-259 (1994).
	DN	Hsyu, P.H. et al., 1997, "Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers", J. Clin. Pharmacol. 37(8):737-743.
	DO	Hsyu, P.H. et al., 10 November 1997 Chemical Abstracts 127(19): Abstract no. 257089; Columbus, Ohio.
	DP	Janowsky, A., et al., J. Neurochem. 46:1272-1276 (1986).
	DQ	Kelley, J.L. et al., 1996, "(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: a novel antidepressant agent and selective inhibitor of norepinephrine uptake", J. Med. Chem. 39:347-349.
	DR	Ketter, T.A. et al., 1995, "Carbamazepine but not valproate induces bupropion metabolism", J. Clin. Psychopharmacol. 15(5):327-333.
	DS	Laizure, S.C. et al., 1985, "Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose", Clin. Pharmacol. Ther. 38:586-589.
	DT	Lief, H.I., 1996, "Bupropion treatment of depression to assist smoking cessation", Am. J. Psychiatry 153(3):442.
	DU	Little, K.Y. et al., 1993, "[¹²⁵ I]RTI-55 binding to cocaine-sensitive dopaminergic and serotonergic uptake sites in the human brain", J. Neurochem. 61:1996-2006.
	DV	Martin, P. et al., 1990, "Antidepressant Profile of Bupropion and Three Metabolites in Mice," Pharmacopsychiatry 23:187-194.
	DW	McNamee et al., 1986, "Stimulation of substrate oxidation in rat hepatic mitochondria following pretreatment with appetite modifying drugs", J. Pharm. Pharmacol. 37:147.
	DX	Merskey, H., 1965, "The effect of chronic pain upon the response to noxious stimuli by psychiatric patients," J. Psychosom. Res. 8:405-419.
	DY	Michell, G.F. et al., 1989, "Effect of bupropion on chocolate craving", Am. J. Psychiatry 146(1):119-120.
	DZ	Michell, G.F. et al., 1989, "Dr. Mitchell and associates reply", Am. J. Psychiatry 146(8):1089.
	EA	Moisset, B., et al., Brain Res. 92:157-164 (1975).
	EB	Moret, C. & Brile, M., 1988, "Sensitizing of the response of 5-HT autoreceptors to drugs modifying synaptic availability of 5-HT", 27(1):43-49.
	EC	Musso et al., 1993, "Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion", Chirality 5:495-500.
	ED	Musso et al., 1997, "Synthesis and Evaluation of the Anticonvulsant Activity of a Series of 2-Amino-Phenyl-1-Propanols Derived from the Metabolites of the Antidepressant Bupropion," Bioorganic & Medical Chemistry Letters, Vol. 7 No 1, pp 1-6, 1997.
	EE	Nomikos et al., 1992, "Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum", Neuropsychopharmacology 7(1):7-14.
	EF	Nutt, D.J. et al., 1981, "Studies on the postictal rise in seizure threshold," Eur. J. Pharmacol. 71:287-295.
	EG	Nutt, D.J. Et al, 1980, "On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock," Neuropharmacology 19:1017-1023.
12	EH	Olsen et al., 1985, "Benzodiazepine/ γ -aminobutyric acid receptor deficit in the midbrain of the seizure-susceptible gerbil", PNAS USA 82:6701-6705.




RECEIVED
JUL 30 2001
TECH CENTER 1800/2801

NI	EI	Pearlstein et al., 1997, "Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder", J. Clin. Psychopharmacol. 17(4):261-266.
	EJ	Physician's Desk Reference®, 1998, pages 1120-1127.
	EK	Popli, A.P. et al., 1994, "Antidepressant-associated seizures", J. Clin. Psych. 55(6):267.
	EL	Popli, A. et al., 1995, "Bupropion and anticonvulsant drug interactions", Annals of Clin. Psychiatry 7(2):99-101.
	EM	Posner, J. et al., 1985, "The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses", Eur. J. Clin. Pharmacol. 29:97-103.
	EN	Potter, W.Z. & Manji, H.K., 1990, "Antidepressants, metabolites, and apparent drug resistance", Clin. Neuropharmacol. 13(1):S45-S53.
	EO	Remingtons: The Practice of the Science and Pharmacy, 19th ed., Gennaro, ed., p. 1625 (1995).
	EP	Rose, J.E., 1996, "Nicotine addiction and treatment", Annu. Rev. Med. 47:493-507.
	EQ	Rosenstein, D.L. et al., 1993, "Seizures associated with antidepressants: a review", J. Clin. Psychiatry 54(8):289-299.
	ER	Rudorfer, M.V. et al., 1994, "Comparative tolerability profiles of the newer versus older antidepressants", Drug Safety 10(1):18-46.
	ES	Schroeder, D.H., 1983, "Metabolism and kinetics of bupropion", J. Clin. Psychiatr. 44(5):79-81.
	ET	Schroeder, D.H. et al., 1979, "The isolation and identification of some basic urinary metabolites of bupropion - HCL in man", The Pharmacologist 21(3):191.
	EU	SCRIP Bupropion Sustained Release (SR) for Smoking Cessation, 12/18/96.
	EV	SCRIP Itraconazole for "pulse" dosing of onychomycosis, 12/18/96.
	EW	Stathis, M. et al., 1995, "Rate of binding of various inhibitors at the dopamine transporter in vivo", Psychopharmacol. 119:376-384.
	EX	Storrow, A.B., 1994, "Bupropion overdose and seizure", Am. J. Emerg. Med. 12:183-184.
	EY	Suckow, R.F. et al., 1986, "Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs", Drug Metab. Dispos. 14(6):692-697.
	EZ	Suckow, R.F. et al., 1997, "Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography", Biomedical Chromatog. 11:174-179.
NI	FA	Sulser, F., 1983, "Molecular mechanisms in antidepressant action," Psychopharmacol. Bull. 19(3):300.
	FB	Sweet, R.A. et al., 1995, "Pharmacokinetics of single- and multiple- dose bupropion in elderly patients with depression", J. Clin. Pharmacol. 35:876-884.
	FC	Testa B. and Trager, W.F., 1990, "Racemates Versus Enantiomers in Drug Development: Dogmatism or Pragmatism?" Chirality 2:129-133.
	FD	Vassout, A. et al., 1993, "Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants", J. Receptor Res. 13(1-4):341-354.
	FE	Ward, N.G., 1990, <u>The Management of Pain</u> , Second Edition, Vol. 1, Chapter 18 (eds.) Bonica, J.J. pp. 310-319.
	FF	Ward, R. et al., 1971, "Asymmetric audiogenic seizures in mice: a possible analogue of focal epilepsy", Brain Res. 31:207-210.
	FG	Welch, R.M. et al., 1987, "Pharmacological significance of the species differences in bupropion metabolism", Neurobiol. 17(3):287-298.



	FH	Wilens, S.H., 1972, <u>Tables of Resolving Agents and Optical Resolutions</u> , Univ. of Notre Dame Press, Notre Dame, IN.
	FI	Wright et al., 1985, "Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects", J. Clin. Psych. 46(1):22-25.
	FJ	Zarrindast et al., 1988, "Anorectic and behavioral effects of bupropion", Gen. Pharmacology 19(2):201-204.
EXAMINER <i>R Cook</i>		DATE CONSIDERED <i>11/1/01</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



RECEIVED
JUL 30 2001
TECH CENTER 1600/2900